Study guide

2.1 Coronary Artery Disease & Acute Myocardial Infarction

Combined Medical Services Examination UPSC CMS

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Logistics & Pattern

1.1 UPSC CMS Examination Overview & Eligibility 1.2 Two-Paper Written Exam Pattern & Negative Marking 1.3 Personality Test, Service Allocation & Career Paths

2 Chapter 2: General Medicine - Cardiology & Respiratory

2.1 Coronary Artery Disease & Acute Myocardial Infarction 2.2 Heart Failure & Cardiac Arrhythmias 2.3 Community-Acquired Pneumonia & Pulmonary Tuberculosis 2.4 COPD, Bronchial Asthma & Pulmonary Embolism

3 Chapter 3: General Medicine - Gastroenterology & Hepatology

3.1 Peptic Ulcer Disease & Upper GI Bleeding 3.2 Liver Cirrhosis & Portal Hypertension 3.3 Acute & Chronic Viral Hepatitis & Pancreatitis 3.4 Inflammatory Bowel Disease & Malabsorption Syndromes

4 Chapter 4: General Medicine - Nephrology & Endocrinology

4.1 Acute Kidney Injury & Chronic Kidney Disease 4.2 Glomerulonephritis, Nephrotic Syndrome & Electrolyte Imbalances 4.3 Diabetes Mellitus: Diagnosis, Complications & Management 4.4 Thyroid Disorders & Adrenal Gland Dysfunction

5 Chapter 5: General Medicine - Neurology, Haematology & Infection

5.1 Cerebrovascular Accidents (Stroke) & Epilepsy 5.2 Approach to Anaemia: Microcytic, Megaloblastic & Haemolytic 5.3 Acute & Chronic Leukaemias and Lymphomas 5.4 Tropical & Endemic Infections: Malaria, Typhoid & Dengue

6 Chapter 6: General Medicine - Emergency Medicine & Toxicology

6.1 Acute Anaphylaxis, Sepsis & Cardiopulmonary Resuscitation 6.2 Organophosphate, Paracetamol & Snakebite Toxicology 6.3 Common Dermatological & Psychiatric Manifestations in Internal Medicine 6.4 Musculoskeletal System & Adult Rheumatology

7 Chapter 7: Paediatrics - Neonatology & Child Growth

7.1 Newborn Care, Neonatal Resuscitation & APGAR Score 7.2 Prematurity, Low Birth Weight & Neonatal Jaundice 7.3 Infant & Child Growth & Developmental Milestones

8 Chapter 8: Paediatrics - Child Health & Nutrition

8.1 Protein-Energy Malnutrition (PEM) & Micronutrient Deficiencies 8.2 Universal Immunization Programme (UIP) & Child Vaccines 8.3 Pediatric Diarrhoea, Dehydration & Respiratory Emergencies 8.4 Birth Defects, Genetic Counseling, Autism & Paediatric Accidents/Poisoning

9 Chapter 9: Surgery - General Surgery, Wounds & Shock

9.1 Wound Healing, Surgical Site Infections & Gas Gangrene 9.2 Pathophysiology of Shock & Perioperative Fluid Therapy 9.3 Acute Abdomen: Appendicitis, Peritonitis & Intestinal Obstruction 9.4 Classification, Resuscitation & Management of Thermal Burns 9.5 Medicolegal & Ethical Issues in Surgery

10 Chapter 10: Surgery - Surgical Specialties I

10.1 Inguinal, Femoral & Ventral Hernias 10.2 Benign Breast Diseases & Breast Carcinoma 10.3 Solitary Thyroid Nodule & Thyroid Carcinoma 10.4 Benign Prostatic Hyperplasia & Renal Calculi

11 Chapter 11: Surgery - ENT, Orthopaedics & Anaesthesia

11.1 Acute Otitis Media, Tonsillitis & Epistaxis 11.2 Cataract, Glaucoma & Red Eye Emergencies 11.3 Principles of Fracture Management & Common Dislocation 11.4 Principles of Local, Regional & General Anaesthesia 11.5 Neurosurgery: Raised ICP, Head Injury & CNS Lesions 11.6 Thoracic Surgery: Chest Trauma, Pleural & Lung Disease

12 Chapter 12: Obstetrics - Antenatal Care & Complications

12.1 Antenatal Care, Maternal Nutrition & Fetal Assessment 12.2 Preeclampsia, Eclampsia & Gestational Hypertension 12.3 Antepartum Haemorrhage: Placenta Previa & Abruptio Placentae 12.4 Anemia in Pregnancy & Gestational Diabetes Mellitus 12.5 Spontaneous & Recurrent Abortion: Recognition & Management

13 Chapter 13: Obstetrics & Gynaecology - Labor & PPH

13.1 Normal Labor Mechanisms & Partograph Monitoring 13.2 Malpresentations, Breech & Obstructed Labor 13.3 Postpartum Haemorrhage (PPH) Causes & Management 13.4 Puerperal Sepsis & Postnatal Maternal Care

14 Chapter 14: Gynaecology & Family Planning

14.1 Abnormal Uterine Bleeding & Uterine Fibroids 14.2 Cervical Screening (Pap Smear) & Pelvic Inflammatory Disease 14.3 Temporary & Permanent Contraceptive Methods in India 14.4 Medical Termination of Pregnancy (MTP): Law & Methods

15 Chapter 15: PSM - Epidemiology & Biostatistics

15.1 Principles of Epidemiology & Disease Transmission 15.2 Observational & Experimental Epidemiological Study Designs 15.3 Evaluation of Screening Tests: Sensitivity, Specificity & Predictive Value 15.4 Biostatistics: Sampling, Central Tendency & Significance Testing

16 Chapter 16: PSM - Disease Epidemiology & Programmes

16.1 Epidemiology & Control of TB, Malaria & Dengue 16.2 National Tuberculosis Elimination Programme & NVBDCP 16.3 Epidemiology of Hypertension, Diabetes & Cancer in India 16.4 Cold Chain Management & Vaccine Logistics in India 16.5 Genetics and Health: Inheritance, Screening & Counseling

17 Chapter 17: PSM - Health Planning & Environmental Health

17.1 Demography, Fertility Rates & Family Welfare Indicators 17.2 Safe Water Supply, Waste Disposal & Air Pollution 17.3 Occupational Health Hazards & Pneumoconioses 17.4 Health Care Delivery System, Ayushman Bharat & National Health Mission 17.5 International Health: WHO, Global Agencies & SDG 3 17.6 Medical Sociology & Health Education

2.1 Coronary Artery Disease & Acute Myocardial Infarction

Key Takeaways Explain This Topic AI

ST-elevation myocardial infarction (STEMI) requires immediate reperfusion with Primary Percutaneous Coronary Intervention (PCI) within 90 minutes door-to-balloon time, or thrombolysis within 30 minutes door-to-needle time if PCI is unavailable and presentation is <12 hours.

Cardiac Troponin I/T is the most sensitive and specific biomarker for myocardial injury, remaining elevated for 7-14 days, whereas CK-MB peaks at 24 hours and normalizes within 48-72 hours, making CK-MB the biomarker of choice to diagnose early re-infarction.

ECG wall localization relies on lead patterns: Anterior/Anteroseptal (LAD, V1-V4), Inferior (RCA, II, III, aVF), Lateral (LCX, I, aVL, V5-V6), and Right Ventricular (V4R, requiring avoidance of nitrates/morphine and aggressive IV fluid resuscitation).

Mechanical complications of MI include papillary muscle rupture causing acute severe mitral regurgitation, free wall rupture leading to cardiac tamponade, and ventricular septal defect (VSD) producing a new harsh holosystolic murmur, typically occurring 3 to 5 days post-infarction.

Last updated: July 2026

  • Coronary Artery Disease & Acute Myocardial Infarction
  • 1. Pathophysiology & Atherosclerotic Cascade

Coronary Artery Disease (CAD) arises from the progressive deposition of lipids, inflammatory cells, and fibrous tissue within the intima of epicardial coronary arteries, forming atherosclerotic plaques.

Stable Plaque: Thick fibrous cap with a dense lipid core, causing predictable exertional ischemia when luminal obstruction exceeds 70% (Stable Angina).

Vulnerable Plaque: Thin cap fibroatheroma (TCFA) rich in macrophages and lipids. Plaque fissure, erosion, or rupture exposes subendothelial collagen and tissue factor to circulation, triggering rapid platelet activation, aggregation, and thrombosis.

Partial/Transient Occlusion: Manifests clinically as Unstable Angina (UA) or Non-ST-Elevation Myocardial Infarction (NSTEMI) depending on the presence of myocardial necrosis biomarkers.

Complete Transmural Occlusion: Leads to ST-Elevation Myocardial Infarction (STEMI) , resulting in ischemic necrosis propagating from endocardium to epicardium over 6 hours.

2. Clinical Classification & Diagnostic Spectrum

Category Chest Pain Characteristics Biomarkers (Troponin) ECG Findings Pathophysiology

Stable Angina Exertional, relieved by rest/sublingual nitroglycerin within 5 min Normal Normal or transient ST depression during stress Fixed luminal stenosis (>70%) without acute thrombosis

Unstable Angina Occurs at rest, new onset (<2 months), or crescendo pattern Normal ST depression, T-wave inversion, or normal Non-occlusive thrombus on ruptured plaque

NSTEMI Persistent, severe rest pain (>20 min), poor response to nitrates Elevated ST depression, T-wave inversion, or non-specific ST-T changes Subendocardial necrosis due to incomplete/transient occlusion

STEMI Crushing retrosternal pain radiating to jaw/left arm, autonomic symptoms Elevated ST elevation (≥1 mm in ≥2 contiguous leads or new LBBB) Transmural necrosis due to complete epicardial artery occlusion

Clinical Gem (UPSC CMS Focus): Prinzmetal (Variant) Angina is caused by focal coronary artery vasospasm (often at sites of minor plaque). It presents with rest chest pain occurring predominantly at night or early morning, accompanied by transmural transient ST elevation on ECG, but with normal cardiac biomarkers . It responds promptly to sublingual nitrates and Calcium Channel Blockers (Diltiazem/Amlodipine); Beta-blockers are contraindicated as they worsen un-opposed alpha-adrenergic vasospasm.

3. ECG Localization & Coronary Anatomy Correlation

Localization of the culprit vessel is paramount for predicting hemodynamic complications and guiding invasive coronary angiography:

Infarct Location Contiguous ECG Leads Culprit Coronary Artery Hemodynamic & Clinical Pearls

Anteroseptal V1, V2, V3, V4 Left Anterior Descending (LAD) High risk of heart failure, cardiogenic shock, bundle branch blocks

Anterolateral / Extensive V1 - V6, I, aVL Main Stem / Proximal LAD Large area of necrosis; anterior wall aneurysm risk

Inferior II, III, aVF Right Coronary Artery (RCA) (~85%) or LCX (~15%) Associated with sinus bradycardia, AV blocks (increased vagal tone), nausea

Right Ventricular (RV) V3R, V4R (ST elevation ≥1 mm) Proximal RCA Triad: Hypotension, clear lung fields, elevated JVP. Preload dependent!

Lateral I, aVL, V5, V6 Left Circumflex (LCX) or Diagonal LAD Isolated high lateral MI may show changes only in I and aVL

True Posterior ST depression in V1–V3 with tall R waves & upright T waves LCX or Distal RCA Mirror test: Invert V1-V3 ECG tracing to reveal classic ST elevation

Critical Guideline: In any patient presenting with an Inferior MI (ST elevation in II, III, aVF) , right-sided ECG leads (V3R–V6R) MUST be obtained immediately. If RV infarction is confirmed:

AVOID Nitrates, Morphine, and Diuretics (these reduce preload and precipitate severe, fatal hypotension).

Primary treatment consists of aggressive IV isotonic saline (0.9% NaCl) boluses to maintain right ventricular preload and cardiac output.

4. Cardiac Biomarkers Dynamics

Understanding the temporal profile of cardiac enzymes is crucial for both initial diagnosis and detecting early re-infarction:

Cardiac Troponin I & T (cTnI / cTnT):

Initial Rise: 3–4 hours after myocardial injury.

Peak: 18–24 hours.

Duration of Elevation: 7–14 days.

Clinical Significance: Gold standard for diagnosing MI. High sensitivity assays detect minor myocardial necrosis.

Creatine Kinase-MB (CK-MB):

Initial Rise: 4–6 hours.

Peak: 12–24 hours.

Duration of Elevation: Normalizes within 48–72 hours .

Clinical Significance: Because troponin remains elevated for up to two weeks, CK-MB is the diagnostic biomarker of choice for detecting recurrent re-infarction occurring within 3 to 10 days after the index event.

Myoglobin:

Initial Rise: 1–2 hours (earliest marker).

Duration: Normalizes within 24 hours. Lack of specificity limits its utility.

  • 5. Emergency Management Protocols & Reperfusion Strategies
  • Immediate Medical Therapy (MONAH Protocol)

Aspirin: 300 mg chewed immediately (non-enteric coated) to achieve rapid antiplatelet inhibition.

P2Y12 Inhibitor: Loading dose of Ticagrelor (180 mg) or Prasugrel (60 mg) ; Clopidogrel (300–600 mg) is used if thrombolysis is planned or contraindications exist.

Nitrates: Sublingual Nitroglycerin (0.4 mg every 5 min up to 3 doses) for chest pain, unless SBP <90 mmHg, HR <50 or >100 bpm, or RV infarction is present.

Analgesia: IV Morphine (2–4 mg) for severe refractory chest pain (used judiciously due to potential delay in oral antiplatelet absorption).

Oxygen: Indicated ONLY if arterial oxygen saturation ( S p O 2 SpO_2 Sp O 2 ​ ) is <90% or patient is in respiratory distress (routine oxygen in normoxic patients causes coronary vasoconstriction via reactive oxygen species).

Anticoagulation: Unfractionated Heparin (UFH) IV bolus or Enoxaparin SC.

Reperfusion Windows in STEMI

Reperfusion must be initiated rapidly for all patients presenting within 12 hours of symptom onset with persistent ST elevation:

Primary Percutaneous Coronary Intervention (PCI): Preferred reperfusion strategy.

Target Door-to-Balloon Time: ≤90 minutes (if presenting to a PCI-capable facility).

Target Transfer Time: ≤120 minutes from first medical contact (FMC) to balloon inflation if transferred from a non-PCI facility.

Fibrinolytic / Thrombolytic Therapy: Indicated when Primary PCI cannot be performed within 120 minutes of FMC.

Target Door-to-Needle Time: ≤30 minutes .

Preferred Agents: Fibrin-specific agents (Tenecteplase weight-adjusted single IV bolus, Reteplase, or Alteplase) are superior to Streptokinase (1.5 million units IV over 60 min).

Thrombolytic Contraindications (High-Yield UPSC CMS Checklist)

  • Absolute Contraindications Relative Contraindications
  • Any prior intracranial hemorrhage (ICH) Severe uncontrolled hypertension (SBP >180 mmHg or DBP >110 mmHg)
  • Known structural cerebrovascular lesion (e.g., AV malformation) Ischemic stroke >3 months prior
  • Known malignant intracranial neoplasm Prolonged or traumatic CPR (>10 minutes)
  • Ischemic stroke within the preceding 3 months (excluding acute within 4.5h) Major surgery within <3 weeks
  • Suspected aortic dissection Active peptic ulcer disease

Active bleeding or bleeding diathesis (excluding menses) Current use of oral anticoagulants (higher INR = higher risk)

  • Significant closed-head or facial trauma within 3 months Pregnancy or within 1 week postpartum
  • 6. Post-MI Complications & Long-Term Management

Complications follow a distinct chronological sequence post-MI:

Arrhythmias (Hours 0–24): Ventricular Fibrillation (VF) and Ventricular Tachycardia (VT) are the leading cause of pre-hospital sudden cardiac death. Managed with unsynchronized defibrillation (VF/pulseless VT) or IV Amiodarone.

Acute Pericarditis (Days 1–3): Sharp pleuritic chest pain radiating to the trapezius ridge, relieved by leaning forward. Shows diffuse concave ST elevation and PR depression on ECG. Treated with High-dose Aspirin (650 mg tid); NSAIDs/corticosteroids should be avoided as they impair myocardial scar formation.

Myocardial Rupture Syndromes (Days 3–14):

Free Wall Rupture: Sudden electromechanical dissociation, cardiac tamponade, death.

Ventricular Septal Rupture (VSD): New loud holosystolic murmur at left lower sternal border with thrill, acute biventricular failure.

Papillary Muscle Rupture (Posteromedial papillary muscle supplied solely by RCA): Sudden onset severe dyspnea, flash pulmonary edema, new apical pansystolic murmur radiating to axilla (Acute Severe Mitral Regurgitation).

Dressler Syndrome (Weeks 2–10): Autoimmune pleuropericarditis presenting with fever, pericardial friction rub, pleuritic pain, and elevated ESR/CRP. Managed with Aspirin + Colchicine.

Secondary Prevention (The 5 Essential Drug Classes)

Dual Antiplatelet Therapy (DAPT): Aspirin (75–100 mg daily) + P2Y12 inhibitor for at least 12 months .

High-Intensity Statin: Atorvastatin 80 mg or Rosuvastatin 40 mg daily (target LDL-C <55 mg/dL).

Beta-Blockers: (e.g., Metoprolol succinate, Bisoprolol, Carvedilol) initiated within 24 hours if hemodynamically stable; reduces myocardial oxygen demand and sudden cardiac death risk.

ACE Inhibitors / ARBs: Initiated within 24 hours, especially in anterior MI, LVEF ≤40%, or hypertension; prevents adverse ventricular remodeling.

Mineralocorticoid Receptor Antagonists (MRA): (Spironolactone or Eplerenone) indicated if LVEF ≤40% and patient has clinical heart failure or diabetes.

Loading diagram... STEMI Emergency Reperfusion Triage & Management Algorithm